MX9305056A - Composicion reguladora de apoptosis. - Google Patents

Composicion reguladora de apoptosis.

Info

Publication number
MX9305056A
MX9305056A MX9305056A MX9305056A MX9305056A MX 9305056 A MX9305056 A MX 9305056A MX 9305056 A MX9305056 A MX 9305056A MX 9305056 A MX9305056 A MX 9305056A MX 9305056 A MX9305056 A MX 9305056A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
apoptosis
agents
salts
regulatory composition
Prior art date
Application number
MX9305056A
Other languages
English (en)
Inventor
Hitomi Iba
Kazuyoshi Kawai
Hiroyuki Ichikawa
Seiji Akamatsu
Fumio Saitoh
Michiaki Tominaga
Masakazu Adachi
Satoru Nakai
Koutoku Aihara
Hideo Tanaka
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX9305056A publication Critical patent/MX9305056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proveen composiciones reguladoras de apoptosis, cada una comprendiendo un miembro seleccionado de una serie de derivados de carboestirilo y sales de los mismos, incluyendo derivados de carboestirilo de la fórmula general (I) (Ver Fórmula); y sales de los mismos, como un ingrediente activo. Las composiciones reguladoras de apoptosis de la invención son útiles como agentes anticáncer, agentes antirretrovirus, agentes terapéuticos para enfermedades autoinmunes, agentes terapéuticos para trombocitopenia, agentes terapéuticos para la enfermedad de Alzheimer, agentes terapéuticos para enfermedades del hígado, de inhibidores de metástasis de cáncer, entre otros.
MX9305056A 1992-08-19 1993-08-19 Composicion reguladora de apoptosis. MX9305056A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22037392 1992-08-19

Publications (1)

Publication Number Publication Date
MX9305056A true MX9305056A (es) 1994-04-29

Family

ID=16750110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305056A MX9305056A (es) 1992-08-19 1993-08-19 Composicion reguladora de apoptosis.

Country Status (8)

Country Link
US (2) US5464833A (es)
EP (1) EP0623598A4 (es)
AU (1) AU666577B2 (es)
CA (1) CA2121148A1 (es)
MX (1) MX9305056A (es)
PH (1) PH30152A (es)
TW (1) TW240168B (es)
WO (1) WO1994004504A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521185A (en) * 1993-03-02 1996-05-28 Otsuka Pharmaceutical Co., Ltd. Methods for inhibiting graft rejection and IL-1 production
US5497913A (en) * 1993-12-15 1996-03-12 Denny D. Baker Mixing bag arrangement and method
EP0711356A4 (en) * 1994-05-26 1999-11-24 New York Medical College DETECTION OF HALOGEN PRECURSORS INCORPORATED IN DNA
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US5620888A (en) * 1994-12-29 1997-04-15 Lxr Biotechnology, Inc. Cell strains for use in identifying potentially therapeutically effective agents
US5571523A (en) * 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
WO1998046229A1 (fr) * 1995-06-21 1998-10-22 Otsuka Pharmaceutical Co., Ltd. Inhibiteurs de la production d'il-8 et du mcaf
WO1997008345A1 (en) * 1995-08-30 1997-03-06 New York Medical College Methods for labeling dna ends with halogenated nucleotides and detecting same with antibodies
US5846758A (en) * 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
JP2000505471A (ja) * 1996-02-28 2000-05-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲン受容体拮抗物質
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US20020151063A1 (en) * 1996-08-30 2002-10-17 Annette Lasham Methods for modulating apoptotic cell death
US5912168A (en) * 1996-08-30 1999-06-15 Genesis Research & Development Corporation Limited CD95 regulatory gene sequences
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
AU6854398A (en) * 1997-04-25 1998-11-24 Otsuka Pharmaceutical Co., Ltd. Hyaluronate synthesis inhibitors
TWI244484B (en) * 1998-06-09 2005-12-01 Takara Bio Inc Pharmaceutical composition containing oxy-containing hexacyclic compound
ES2533255T3 (es) 1998-07-13 2015-04-08 Board Of Regents, The University Of Texas System Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
AU5877500A (en) * 1999-06-15 2001-01-02 Neurogen Corporation Piperidinyl and piperazinyl substituted benzofused lactams
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
WO2002098425A1 (en) * 2001-06-04 2002-12-12 Cytovia, Inc. Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
US7354928B2 (en) * 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
CN104225610B (zh) 2002-07-15 2017-03-01 得克萨斯大学体系董事会 与阴离子磷脂和氨基磷脂结合的选定抗体及其治疗用途
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
CA2553690C (en) 2004-01-22 2016-05-24 Sung Lan Hsia Topical co-enzyme q10 formulations and methods of use
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
GB2532990A (en) 2014-12-05 2016-06-08 Schlumberger Holdings Corrosion inhibition
GB2543498A (en) * 2015-10-19 2017-04-26 Schlumberger Holdings Corrosion inhibition
CN107174584B (zh) * 2016-03-12 2020-09-01 福建金乐医药科技有限公司 含哌嗪结构化合物在制备lsd1抑制剂中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2931741A1 (de) * 1979-08-04 1981-02-26 Thomae Gmbh Dr K Arzneimittel zur vermeidung von tumormetastierung
JPS6038384B2 (ja) * 1978-03-24 1985-08-31 大塚製薬株式会社 チオセミカルバゾン誘導体
JPS5742673A (en) * 1980-08-29 1982-03-10 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5777676A (en) * 1980-10-31 1982-05-15 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5883677A (ja) * 1981-11-11 1983-05-19 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS5929667A (ja) * 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体および強心剤
JPS59104378A (ja) * 1982-12-03 1984-06-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US4677112A (en) * 1984-02-02 1987-06-30 Warner-Lambert Company 1,2,3,4-tetrahydro-2-oxo-8-quinolineacetic and -propanoic acids and derivatives as cognition activators
US4582909A (en) * 1984-02-02 1986-04-15 Warner-Lambert Company Benzobicyclic lactam acids and derivatives as cognition activators
JPH07100696B2 (ja) * 1984-12-18 1995-11-01 大塚製薬株式会社 カルボスチリル誘導体
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
DE3526044A1 (de) * 1985-07-20 1987-01-22 Hoechst Ag Dihydrochinolinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung, sowie zwischenprodukte zu ihrer herstellung
JPS62135423A (ja) * 1985-12-09 1987-06-18 Otsuka Pharmaceut Co Ltd 低酸素症改善剤
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
JPS63225357A (ja) * 1987-03-12 1988-09-20 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US5185346A (en) * 1988-11-29 1993-02-09 Hanssen Pharmaceutica (1H-azol-1-ylmethyl)substituted quinoline derivatives
TW201305B (es) * 1991-04-03 1993-03-01 Otsuka Pharma Co Ltd
DE69230131T2 (de) * 1991-07-03 2000-03-02 Otsuka Pharmaceutical Co., Ltd. Apoptoseregulator
JPH05320133A (ja) * 1991-07-18 1993-12-03 Japan Tobacco Inc ３，４−ジヒドロ−２（１ｈ）−キノリノン誘導体
JP2597953B2 (ja) * 1991-12-10 1997-04-09 大塚製薬株式会社 制癌剤
JPH0612248A (ja) * 1992-04-02 1994-01-21 Hitachi Ltd プログラムの自動生成方式

Also Published As

Publication number Publication date
AU4761593A (en) 1994-03-15
EP0623598A1 (en) 1994-11-09
EP0623598A4 (en) 1997-05-02
AU666577B2 (en) 1996-02-15
US5464833A (en) 1995-11-07
WO1994004504A1 (en) 1994-03-03
US5691341A (en) 1997-11-25
PH30152A (en) 1997-01-21
CA2121148A1 (en) 1994-03-03
TW240168B (es) 1995-02-11

Similar Documents

Publication Publication Date Title
MX9305056A (es) Composicion reguladora de apoptosis.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
UY26968A1 (es) Agentes terapéuticos
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
ES2161290T3 (es) Derivados de quinazolina.
ES2196377T3 (es) Derivados de naftiridina.
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
AR029766A1 (es) Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica
ES2112650T3 (es) Sales de un derivado de indol antimigraña.
ES2185999T3 (es) Derivados de quinazolina y composiciones farmaceuticas que los contienen.
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
MX9304138A (es) Derivados de indol e indeno, procedimiento para supreparacion y composiciones farmaceuticas que los contienen.
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
PA8507601A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
AR008164A1 (es) Cetolidas 6-0-sustituidas que tienen actividad antibacteriana, procedimientos para su preparacion, uso de los mismos en la preparacion decomposiciones farmaceuticas y composiciones farmaceuticas
AR030933A1 (es) Derivados del triazol y composiciones farmaceuticas que los contienen
PA8591701A1 (es) Derivados de pirrolopirimidina
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
AR028948A1 (es) Compuestos novedosos